Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a ...
SpringWorks Therapeutics is a clinical-stage bi...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Rubius Therapeutics developed our proprietary RED PLATFORMÂŽ to generate red blood...
Rubius Therapeutics developed our proprietary R...
Join the National Investor Network and get the latest information with your interests in mind.